MENU
+Compare
ANTX
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$1.27
Change
-$0.00 (-0.00%)
Capitalization
37.95M

ANTX AN2 Therapeutics Forecast, Technical & Fundamental Analysis

Industry Biotechnology
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ANTX with price predictions
Jan 14, 2025

ANTX's Stochastic Oscillator sits in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANTX advanced for three days, in of 158 cases, the price rose further within the following month. The odds of a continued upward trend are .

ANTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ANTX as a result. In of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ANTX moved below its 50-day moving average on January 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.433) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). ANTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ANTX is expected to report earnings to fall 37.21% to -27 cents per share on March 27

AN2 Therapeutics ANTX Stock Earnings Reports
Q4'24
Est.
$-0.27
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.13
Q1'24
Beat
by $0.06
Q4'23
Est.
$-0.57
The last earnings report on November 13 showed earnings per share of -43 cents, beating the estimate of -44 cents. With 89.78K shares outstanding, the current market capitalization sits at 37.95M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Managed Health Care
Address
1800 El Camino Real
Phone
+1 650 331-9090
Employees
41
Web
https://www.an2therapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

ANTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with SYBX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then SYBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
N/A
SYBX - ANTX
60%
Loosely correlated
+0.69%
SNBIF - ANTX
33%
Loosely correlated
N/A
QRON - ANTX
22%
Poorly correlated
N/A
CSLLY - ANTX
22%
Poorly correlated
+0.38%
AZTR - ANTX
22%
Poorly correlated
-8.18%
More